Adhesion and migration of extracellular matrix-stimulated breast cancer

被引:47
作者
Bartsch, JE [1 ]
Staren, ED [1 ]
Appert, HE [1 ]
机构
[1] Med Coll Ohio, Dept Surg, Toledo, OH 43614 USA
关键词
adhesion; breast cancer; extracellular matrix; fibronectin; migration; vitronectin;
D O I
10.1016/S0022-4804(03)00004-0
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. Extracellular matrix (ECM) components, such as vitronectin and fibronectin, have been shown to enhance the metastatic potential of breast cancer cells. We hypothesized that ECM binding to integrin receptors on breast cancer cells influenced cellular adhesion and migration. Materials and methods. Adhesion assays were performed using breast cancer cell lines MDA-MB-435 and MDA-MB-231 and various concentrations of vitronectin or fibronectin. Migration assays were performed using the same cell lines and invasion chambers with 8 mum pore polycarbonate membranes. Blocking antibodies and specific peptidomimetic inhibitors to integrin receptors were used to identify the integrin subunits reacting with vitronectin and fibronectin. Results. While both breast cancer cell lines adhered to and migrated toward vitronectin and fibronectin, MDA-ME-435 had a higher maximum binding to vitronectin and MDA-MB-231 had a higher maximum binding to fibronectin. Anti-beta1 antibody inhibited the adhesion and migration of MDA-MB-231 to fibronectin and the adhesion of MDA-MB-231 to vitronectin ut had no effect on vitronectin-induced adhesion or migration of MDA-MB-435. The avbeta3/alphavbeta5 antagonist, SB 265123, inhibited MDA-MB-231 and MDA-MB-435 adhesion and migration to vitronectin but had no effect on migration to fibronectin in either cell line. Conclusions. We conclude that the integrin subunits beta1, alphavbeta3, and alphavbeta5 can be involved in breast cancer cellular adhesion and migration to vitronectin and fibronectin. Because more than one integrin inhibitor was required to block adhesion or migration in the cell lines studied, breast cancer therapy based on integrin antagonists would most likely require concomitant use of multiple agents. (C) 2003 Elsevier Science (USA).
引用
收藏
页码:287 / 294
页数:8
相关论文
共 31 条
  • [1] Disubstituted indazoles as potent antagonists of the integrin αvβ3
    Batt, DG
    Petraitis, JJ
    Houghton, GC
    Modi, DP
    Cain, GA
    Corjay, MH
    Mousa, SA
    Bouchard, PJ
    Forsythe, MS
    Harlow, PP
    Barbera, FA
    Spitz, SM
    Wexler, RR
    Jadhav, PK
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (01) : 41 - 58
  • [2] Fine mapping of inhibitory anti-α5 monoclonal antibody epitopes that differentially affect integrin-ligand binding
    Burrows, L
    Clark, K
    Mould, AP
    Humphries, MJ
    [J]. BIOCHEMICAL JOURNAL, 1999, 344 : 527 - 533
  • [3] Recent insights into the role of integrins in cancer metastasis
    Clezardin, P
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 1998, 54 (06) : 541 - 548
  • [4] Crowe DL, 1999, HISTOL HISTOPATHOL, V14, P665, DOI 10.14670/HH-14.665
  • [5] N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists
    Dechantsreiter, MA
    Planker, E
    Mathä, B
    Lohof, E
    Hölzemann, G
    Jonczyk, A
    Goodman, SL
    Kessler, H
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (16) : 3033 - 3040
  • [6] INTEGRIN-MEDIATED SIGNAL-TRANSDUCTION IN ONCOGENESIS - AN OVERVIEW
    DEDHAR, S
    [J]. CANCER AND METASTASIS REVIEWS, 1995, 14 (03) : 165 - 172
  • [7] The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells
    Doerr, ME
    Jones, JI
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (05) : 2443 - 2447
  • [8] Filardo EJ, 1996, J CELL SCI, V109, P1615
  • [9] FRIEDRICHS K, 1995, CANCER RES, V55, P901
  • [10] Fukushima Y, 1998, INT J CANCER, V76, P63, DOI 10.1002/(SICI)1097-0215(19980330)76:1<63::AID-IJC11>3.0.CO